Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
NCT05430698Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in perihilar cholangiocarcinoma (PHC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: 12-month relapse-free survival rate. Started Jan 2023; status: recruiting.
02
Conditions
perihilar cholangiocarcinoma (PHC)
Beyond the preview
Go deeper on NCT05430698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430698.